Blood
Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy
McMurray JC, Pacheco CS, Schornack BJ, et al.
This study demonstrated that an elevated basal serum tryptase based upon genotype is a highly sensitive and specific screening test for indolent systemic mastocytosis.
Previous Article
- • Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: a nationwide multicenter retrospective analysis.
- • Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy
- • Plasma protein profiling to discern indolent from advanced systemic mastocytosis
- • Indolent systemic mastocytosis (ISM) without skin lesions as a recurrent anaphylaxis: a case report study.
- • Safety of a mRNA COVID-19 vaccine in patients with indolent systemic mastocytosis.
- • Avapritinib versus placebo in indolent systemic mastocytosis.
- • The influence of nutritional habits, body mass index and intestinal microbiota in mastocytosis on clinical symptoms using conventional culture and next generation sequencing.
- • Genome-wide DNA methylation and gene expression in patients with indolent systemic mastocytosis.
- • Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.
- • Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches.
- • Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms.
- • The international consensus classification of mastocytosis and related entities.
- • The Mastocytosis Control Test for Assessing Disease Control
- • The Validated Mastocytosis Control Test for Measuring Disease Control
